GenFleet Therapeutics' GFH375 Granted Breakthrough Designation in China for Lung Cancer

MT Newswires Live

03/02

GenFleet Therapeutics (Shanghai) (HKG:2595) said GFH375 was granted the breakthrough therapy designation in China as a treatment for a type of non-small cell lung cancer, according to a Hong Kong bourse filing Monday.

The company is studying the medicine in patients with KRAS G12D-mutant non-small cell lung cancer patients who have received at least one prior systemic therapy.

The company expects to announce data from ongoing studies of the medicine at global academic events this year.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2616066748"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616066748\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616066748?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 10:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616066748","market":"fut","top_or_hot":-1,"title":"GenFleet Therapeutics' GFH375 Granted Breakthrough Designation in China for Lung Cancer","media":"MT Newswires Live","content":"<html><body><p> GenFleet <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (Shanghai) (HKG:2595) said GFH375 was granted the breakthrough therapy designation in China as a treatment for a type of non-small cell lung cancer, according to a Hong Kong bourse filing Monday.</p><p>The company is studying the medicine in patients with KRAS G12D-mutant non-small cell lung cancer patients who have received at least one prior systemic therapy.</p><p>The company expects to announce data from ongoing studies of the medicine at global academic events this year.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GenFleet Therapeutics' GFH375 Granted Breakthrough Designation in China for Lung Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenFleet Therapeutics' GFH375 Granted Breakthrough Designation in China for Lung Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-03-02 10:47</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> GenFleet <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (Shanghai) (HKG:2595) said GFH375 was granted the breakthrough therapy designation in China as a treatment for a type of non-small cell lung cancer, according to a Hong Kong bourse filing Monday.</p><p>The company is studying the medicine in patients with KRAS G12D-mutant non-small cell lung cancer patients who have received at least one prior systemic therapy.</p><p>The company expects to announce data from ongoing studies of the medicine at global academic events this year.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"半新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2616066748","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616066748","pubTimestamp":1772419655,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"GenFleet Therapeutics   said GFH375 was granted the breakthrough therapy designation in China as a treatment for a type of non-small cell lung cancer, according to a Hong Kong bourse filing Monday.The company is studying the medicine in patients with KRAS G12D-mutant non-small cell lung cancer patients who have received at least one prior systemic therapy.The company expects to announce data from ongoing studies of the medicine at global academic events this year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","02595":"劲方医药-B","BK1161":"生物科技","BK4139":"生物科技","LENZ":"Therapeutics","BK4007":"制药"},"translate_title":"GenFleet Therapeutics的GFH375在中国获得肺癌突破性认定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02595":1,"LENZ":1.5},"content_text":"GenFleet Therapeutics (Shanghai) (HKG:2595) said GFH375 was granted the breakthrough therapy designation in China as a treatment for a type of non-small cell lung cancer, according to a Hong Kong bourse filing Monday.The company is studying the medicine in patients with KRAS G12D-mutant non-small cell lung cancer patients who have received at least one prior systemic therapy.The company expects to announce data from ongoing studies of the medicine at global academic events this year.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}